{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:38:33Z","timestamp":1775129913082,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was supported by Janssen and sponsored by the European Myeloma Network."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic light-chain (AL) amyloidosis is a rare and debilitating disease. Advances have been made in new treatments in recent years, yet real-world data on the management of the disease are scarce. EMN23 is a retrospective, observational study of patients who initiated first-line treatment in 2004\u20132018 in Europe, presenting the demographics, clinical characteristics, treatment patterns, and outcomes, from 4480 patients. Regimens based on bortezomib were the most frequently used as first-line therapy; only 6.2% of the patients received autologous stem cell transplant. Hematologic responses improved post-2010 (67.1% vs 55.6% pre-2010). The median overall survival (OS) was 48.8 (45.2\u201351.7) months; 51.4 (47.3\u201357.7) months pre-2010 and 46.7 (41.3\u201352.2) months post-2010. Early mortality was 13.4% and did not improve (11.4% vs 14.4% pre- and post-2010); furthermore, it remained high in patients with advanced cardiac disease (over 39% for stage IIIb). There was a significant improvement for stage IIIa (14.2 vs 30.7 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.0170) but no improvement for stage IIIb patients (5.0 vs 4.5 months). This European real-world study of AL-amyloidosis emphasizes the unmet needs of early diagnosis, and the lack of improvement in survival outcomes of the frail stage IIIb population, despite the introduction of new therapies in recent years.<\/jats:p>","DOI":"10.1038\/s41408-023-00789-8","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T06:02:53Z","timestamp":1674626573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5138","authenticated-orcid":false,"given":"Giovanni","family":"Palladini","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4853-5579","authenticated-orcid":false,"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7680-3254","authenticated-orcid":false,"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[]},{"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7091-8253","authenticated-orcid":false,"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Bridoux","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[]},{"given":"Sriram","family":"Ravichandran","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-6746","authenticated-orcid":false,"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[]},{"given":"Wilfried","family":"Roeloffzen","sequence":"additional","affiliation":[]},{"given":"M. Teresa","family":"Cibeira","sequence":"additional","affiliation":[]},{"given":"Hermine","family":"Agis","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Bergantim","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-6267","authenticated-orcid":false,"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3978-766X","authenticated-orcid":false,"given":"Cristina","family":"Jo\u00e3o","sequence":"additional","affiliation":[]},{"given":"Alexandros","family":"Leonidakis","sequence":"additional","affiliation":[]},{"given":"Giorgos","family":"Cheliotis","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-7237","authenticated-orcid":false,"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"789_CR1","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641\u201354.","journal-title":"Lancet."},{"key":"789_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Prim. 2018;4:38.","journal-title":"Nat Rev Dis Prim"},{"key":"789_CR3","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi J, Guan J, Jiang B, Brenner DA, Monte FD, Ward JE, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA. 2010;107:4188\u201393.","journal-title":"Proc Natl Acad Sci USA"},{"key":"789_CR4","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","volume":"29","author":"G Merlini","year":"2011","unstructured":"Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924\u201333.","journal-title":"J Clin Oncol"},{"key":"789_CR5","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","volume":"114","author":"JA Vrana","year":"2009","unstructured":"Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114:4957\u20139.","journal-title":"Blood."},{"key":"789_CR6","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1182\/blood-2011-07-365510","volume":"119","author":"F Brambilla","year":"2012","unstructured":"Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood. 2012;119:1844\u20137.","journal-title":"Blood."},{"key":"789_CR7","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","volume":"32","author":"I Lousada","year":"2015","unstructured":"Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32:920\u20138.","journal-title":"Adv Ther"},{"key":"789_CR8","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.2020008737","volume":"139","author":"G Palladini","year":"2022","unstructured":"Palladini G, Merlini G. How I treat AL amyloidosis. Blood. 2022;139:2918\u201330.","journal-title":"Blood."},{"key":"789_CR9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3324\/haematol.11325","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92:1351\u20138.","journal-title":"Haematologica."},{"key":"789_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28:1031\u20137.","journal-title":"J Clin Oncol"},{"key":"789_CR11","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","volume":"119","author":"CP Venner","year":"2012","unstructured":"Venner CP, Lane T, Foard D, Rannigan L, Gibbs SDJ, Pinney JH, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119:4387\u201390.","journal-title":"Blood."},{"key":"789_CR12","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","volume":"119","author":"JR Mikhael","year":"2012","unstructured":"Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119:4391\u20134.","journal-title":"Blood."},{"key":"789_CR13","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","volume":"119","author":"E Kastritis","year":"2012","unstructured":"Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, et al. A phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012;119:5384\u201390.","journal-title":"Blood."},{"key":"789_CR14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","volume":"126","author":"G Palladini","year":"2015","unstructured":"Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126:612\u20135.","journal-title":"Blood."},{"key":"789_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","volume":"130","author":"V Sanchorawala","year":"2017","unstructured":"Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, et al. A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130:597\u2013605.","journal-title":"Blood."},{"key":"789_CR16","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1182\/bloodadvances.2019000147","volume":"3","author":"E Kastritis","year":"2019","unstructured":"Kastritis E, Dialoupi I, Gavriatopoulou M, Roussou M, Kanellias N, Fotiou D, et al. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Adv. 2019;3:3002\u20139.","journal-title":"Blood Adv"},{"key":"789_CR17","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","volume":"38","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38:3252\u201360.","journal-title":"J Clin Oncol"},{"key":"789_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46\u201358.","journal-title":"N Engl J Med"},{"key":"789_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","volume":"36","author":"A Dispenzieri","year":"2022","unstructured":"Dispenzieri A, Kastritis E, Wechalekar AD, Sch\u00f6nland SO, Kim K, Sanchorawala V, et al. A randomized phase 3 study of ixazomib-dexamethasone versus physician\u2019s choice in relapsed or refractory AL amyloidosis. Leukemia. 2022;36:225\u201335.","journal-title":"Leukemia"},{"key":"789_CR20","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129:2111\u20139.","journal-title":"Blood."},{"key":"789_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00529-w","volume":"11","author":"A Staron","year":"2021","unstructured":"Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11:139.","journal-title":"Blood Cancer J"},{"key":"789_CR22","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","volume":"99","author":"A Jaccard","year":"2014","unstructured":"Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-na\u00efve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014;99:1479\u201385.","journal-title":"Haematologica."},{"key":"789_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319\u201328.","journal-title":"Am J Hematol"},{"key":"789_CR24","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541\u20139.","journal-title":"J Clin Oncol"},{"key":"789_CR25","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751\u20137.","journal-title":"J Clin Oncol"},{"key":"789_CR26","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420\u20137.","journal-title":"Blood."},{"key":"789_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989\u201395.","journal-title":"J Clin Oncol"},{"key":"789_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","volume":"29","author":"V Sanchorawala","year":"2022","unstructured":"Sanchorawala V, Boccadoro M, Gertz M, Hegenbart U, Kastritis E, Landau H, et al. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid. 2022;29:1\u20137.","journal-title":"Amyloid."},{"key":"789_CR29","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","volume":"134","author":"R Manwani","year":"2019","unstructured":"Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134:2271\u201380.","journal-title":"Blood."},{"key":"789_CR30","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","volume":"119","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119:4860\u20137.","journal-title":"Blood."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00789-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00789-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00789-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T06:02:58Z","timestamp":1674626578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00789-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00789-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"assertion":[{"value":"2 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GP reports participating in advisory boards for Alexion, Argobio, Janssen, and Protego; honoraria from Alexion, Argobio, Janssen, Protego, The Binding Site, Pfizer, Prothena, Sebia, and Siemens; research funding from Gate bioscience and The Binding Site. SS reports research support from Janssen, Prothena, and Sanofi; participating in advisory boards for Janssen, Telix, and Prothena; honoraria from Janssen, Takeda, Pfizer, and Prothena; travel and congress participation grants from Janssen, Prothena, Celgene, Binding Site, and Jazz. PM reports speaker honoraria from Janssen and Pfizer; participating in advisory board for Janssen. AJ reports honoraria from Servier, Amgen, Abbvie, and Pfizer; participating in advisory committees for Janssen; research funding from Sanofi and Janssen. FB reports lecture fees from Janssen, Astra Zeneca, GSK, and Novartis; consultancy for Janssen and Astra Zeneca. MAD reports honoraria from participation in advisory boards from Amgen, Takeda, Beigene, BMS, and Janssen. UH reports travel grants from Janssen, Prothena, and Pfizer; participating in advisory boards for Pfizer, Janssen, and Prothena; honoraria from Janssen, Pfizer, Alnylam, and Akcea; research funding from Janssen and Prothena. WR reports honoraria\/advisory board from Janssen, MSD, Amgen, and Sanofi. MTC reports honoraria for lectures\/advisory board for Janssen, Amgen, Akcea, and Sanofi. MCC reports honoraria from BMS; consultancy for Janssen-Cilag and Gilead; speaker\u2019s bureau for Medscaoe. RH reports consultancy\/advisory relationship with Janssen, Amgen, Celgene, Abbvie, BMS, Novartis, PharmaMar, and Takeda; honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. CJ reports scientific advisory for Takeda, BMS, Janssen, GSK, and Amgen; research funding from Takeda. AL reports current employment with Health Data Specialists. GC reports current employment with Health Data Specialists. PS reports research support from Janssen, BMS, Sanofi, and Amgen, all for EMN trials; participating in advisory boards for Janssen, BMS, Sanofi, Amgen, Cargen, and Pfizer. EK reports honoraria\/advisory board from Genesis Pharma, Janssen, GSK, and Pfizer; research support from Amgen, Janssen, and Pfizer. AW reports honoraria\/advisory board from Janssen, Alexion, Attralus, Celgene\/BMS, Takeda, and GSK. All remaining authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}